Literature DB >> 21764689

[Overexpression of response gene to complement-32 promotes cytoskeleton reorganization in SW480 cell line].

Jie Tian1, Chuan Xu, Min-hui Yang, Zu-guo Li.   

Abstract

OBJECTIVE: To construct the recombinant plasmid pcDNA3.0-RGC32 and evaluate the effect of the response gene to complement-32 (RGC32) on cell cytoskeleton in vitro.
METHODS: The full-length cDNA of RGC32 was obtained by RT-PCR and inserted into the eukaryotic expression vector pcDNA3.0 to generate the recombinant plasmid pcDNA3.0-RGC32. After transfection of the recombinant plasmid into SW480 cells, the expression of RGC32 in the cells was detected by Western blotting. The cytoskeleton of SW480 cells was visualized before and after the transfection, and the changes in the cell migration ability was assessed by wound-healing assay.
RESULTS: The recombinant plasmid pcDNA3.0-RGC32 was successfully constructed. The expression of RGC32 was significantly increased in SW480 cells after transfection with pcDNA3.0-RGC32. Before the transfection, the microfilaments of SW480 cells were few and short without obvious polarity, but after the transfection, the microfilaments were increased and elongated with also an obvious polarity, and the invasive structures of lamellae and lamellipodia occurred. The migration ability of the cells was enhanced after transfection with pcDNA3.0-RGC32.
CONCLUSION: Overexpression of RGC32 can cause the reorganization of cytoskeleton and promotes the cell migration, which can be an important mechanism of RGC32 in promoting cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764689

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  2 in total

Review 1.  Role of C5b-9 and RGC-32 in Cancer.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Horea Rus
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

2.  Promoter Methylation and mRNA Expression of Response Gene to Complement 32 in Breast Carcinoma.

Authors:  Ebrahim Eskandari-Nasab; Mohammad Hashemi; Firoozeh Rafighdoost
Journal:  J Cancer Epidemiol       Date:  2016-03-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.